middl
east
respiratori
syndrom
coronaviru
merscov
emerg
viru
pose
major
challeng
clinic
manag
proteas
pro
essenti
viral
replic
thu
repres
potenti
target
antivir
drug
develop
present
data
avail
merscov
pro
inhibit
small
molecul
conduct
extens
explor
pharmacophor
space
recent
identifi
set
peptidomimet
inhibitor
bat
pro
pro
share
high
sequenc
ident
merscov
enzym
thu
repres
potenti
surrog
model
antim
drug
discoveri
use
wellestablish
method
quantit
structureact
relationship
qsar
guid
model
dockingbas
compar
intermolecular
contact
analysi
establish
pharmacophor
model
highlight
structur
featur
need
ligand
recognit
reveal
import
bindingpocket
region
involv
pro
ligand
interact
best
model
use
queri
screen
nation
cancer
institut
databas
novel
nonpeptidomimet
pro
inhibitor
identifi
hit
test
merscov
pro
inhibit
two
hit
share
phenylsulfonamid
fragment
show
moder
inhibitori
activ
merscov
pro
repres
potenti
start
point
develop
novel
antim
agent
best
knowledg
first
pharmacophor
model
studi
support
vitro
valid
merscov
pro
merscov
emerg
viru
close
relat
bat
pro
potenti
drug
target
coronaviru
infect
pro
use
surrog
model
identif
merscov
pro
enzym
inhibitor
dbcica
robust
model
method
hit
identif
phenylsulfonamid
scaffold
repres
potenti
start
point
mer
coronaviru
pro
inhibitor
develop
middl
east
respiratori
syndrom
coronaviru
merscov
emerg
viru
caus
sever
pneumonia
ill
exhibit
high
mortal
rate
first
known
human
merscov
case
occur
jordan
caus
viru
detect
identifi
later
year
saudi
arabia
sinc
laboratoryconfirm
case
report
countri
across
world
merscov
envelop
viru
carri
genom
posit
sens
rna
viru
consid
primarili
zoonot
viru
belong
lineag
c
betacoronaviru
thu
close
relat
bat
coronavirus
sever
studi
shown
bat
camel
like
anim
reservoir
merscov
accumul
evid
point
viru
transmiss
dromedari
camel
human
case
mani
viral
diseas
effect
therapi
mer
lack
support
care
avail
treatment
option
attempt
develop
effect
vaccin
merscov
infect
led
promis
result
still
earli
stage
high
morbid
mortal
rate
merscov
well
potenti
caus
epidem
highlight
need
novel
drug
discoveri
develop
effect
safe
antimerscov
therapeut
sever
effort
undertaken
identifi
select
potent
small
molecul
antimerscov
activ
promis
compound
identifi
via
screen
fdaapprov
drug
druglik
small
molecul
use
cellbas
system
vitro
screen
target
homolog
identifi
sever
acut
respiratori
syndrom
coronaviru
sarscov
investig
merscov
review
hilgenfeld
peiri
among
merscov
main
proteinas
also
known
proteas
pro
consid
import
potenti
target
due
essenti
role
viral
life
cycl
coronaviru
genom
encod
replicas
polyprotein
process
pro
yield
intermedi
matur
nonstructur
protein
respons
mani
aspect
viru
replic
enzym
start
attract
interest
target
antimerscov
drug
develop
howev
data
enzym
inhibit
scarc
sarscov
pro
comprehens
explor
drug
target
mani
potent
enzym
inhibitor
identifi
elabor
structureand
ligandbas
silico
model
obtain
use
sarcov
pro
inhibitor
prove
fruitless
identif
merscov
pro
inhibitor
model
studi
conduct
group
data
publish
interestingli
pro
enzym
differ
cov
strain
known
share
signific
sequenc
structur
homolog
provid
strong
structur
basi
design
widespectrum
anticov
inhibitor
sequenc
align
studi
show
activ
site
residu
pro
particip
inhibitor
bind
conserv
merscov
pro
sequenc
ident
pro
figur
therefor
bat
pro
investig
surrog
model
antim
develop
novel
peptidomimet
inhibitor
merscov
pro
identifi
use
enzym
model
studi
use
set
peptidomimet
pro
inhibitor
report
st
john
et
al
conduct
extens
comput
model
studi
model
effort
aim
establish
pharmacophor
model
use
search
queri
virtual
screen
potenti
merscov
pro
inhibitor
method
use
develop
previous
group
qsarguid
pharmacophor
model
dockingbas
compar
intermolecular
contact
analysi
dbcica
pharmacophor
model
model
approach
use
success
identifi
potent
inhibitor
sever
drug
target
identifi
hit
test
vitro
inhibitori
activ
pro
enzym
merscov
chemic
reagent
purchas
sigmaaldrich
unit
state
unless
otherwis
state
estim
extrapol
base
report
inhibitori
percentag
assum
linear
doserespons
relationship
logarithm
measur
ic
valu
use
qsarguid
pharmacophor
model
correl
bioactiv
data
linearli
free
energi
chang
chiral
center
unknown
configur
mark
unknown
invers
chiral
center
sampl
conform
gener
compound
use
explor
pharmacophor
space
pro
seri
establish
model
step
describ
previous
model
workflow
detail
section
qsarguid
select
optim
pharmacophor
conduct
find
optim
combin
pharmacophor
model
capabl
explain
bioactiv
variat
across
whole
set
collect
train
compound
tabl
qsar
model
done
use
genet
function
algorithm
gfa
gener
combin
descriptor
physicochem
pharmacophor
section
subsequ
multipl
linear
regress
mlr
analys
use
assess
qualiti
select
descriptor
combin
ie
explain
bioactiv
variat
within
collect
inhibitor
qsar
model
perform
use
train
set
compound
total
set
pro
inhibitor
valid
use
leaveoneout
r
r
loo
predict
r
r
press
randomli
select
test
set
inhibitor
describ
section
test
set
select
rank
total
inhibitor
accord
ic
valu
everi
fifth
compound
select
test
set
start
highpot
end
dock
studi
perform
use
subset
compound
peptidomimet
pro
inhibitor
known
absolut
stereochemistri
tabl
coordin
pro
retriev
protein
data
bank
pdb
code
protein
structur
modifi
ad
hydrogen
atom
gasteigermarsili
charg
protein
atom
use
discoveri
studio
version
accelri
inc
san
diego
use
subsequ
dock
experi
without
energi
minim
dock
conduct
use
libdock
cdocker
libdock
sitefeatur
dock
algorithm
dock
ligand
remov
hydrogen
atom
activ
site
guid
bind
hotspot
cdocker
charmmbas
simul
annealingmolecular
dynam
method
implement
simul
anneal
search
stabl
dock
ligand
pose
dock
engin
consid
flexibl
ligand
treat
receptor
rigid
detail
dock
engin
correspond
dock
set
describ
section
highestrank
dock
conformerspos
score
use
score
function
jain
pmf
section
dockingscor
cycl
use
engin
repeat
cover
possibl
dock
combin
result
presenc
absenc
crystallograph
explicit
water
molecul
within
bind
site
dockingscor
set
use
dbcica
model
describ
previous
section
describ
detail
dbcica
model
success
dbcica
model
use
guid
manual
build
pharmacophor
section
optim
pharmacophor
structur
ligand
base
valid
use
receiv
oper
characterist
roc
curv
analysi
assess
abil
model
correctli
classifi
group
compound
activ
inact
section
matthew
correl
coeffici
mcc
also
undertaken
addit
valid
addit
exclus
sphere
ad
use
hiphoprefin
modul
discoveri
studio
improv
roc
properti
qsarguid
pharmacophor
section
select
pharmacophor
use
search
queri
screen
nation
cancer
institut
nci
databas
new
pro
inhibitor
hit
captur
qsarguid
pharmacophor
filter
lipinski
criteria
ensur
good
pharmacokinet
properti
smile
arbitrari
target
specif
smart
filter
section
remov
reactiv
ligand
ie
alkyl
halid
michael
acceptor
remain
hit
fit
correspond
individu
pharmacophor
fit
valu
substitut
mlrbase
qsar
model
predict
hit
bioactiv
ic
highestrank
hit
select
vitro
test
use
vote
system
minim
influenc
qsarbas
predict
hit
priorit
system
hit
fit
valu
hit
overal
qsar
predict
cast
vote
one
valu
within
top
captur
hit
otherwis
vote
zero
similarli
hit
captur
success
dbcicaderiv
pharmacophor
pool
togeth
filter
accord
lipinski
criteria
smart
filter
hit
dock
pro
bind
pocket
use
dock
score
condit
success
dbcica
model
result
dock
pose
analyz
critic
contact
accord
success
dbcica
model
sum
critic
contact
hit
compound
use
predict
correspond
ic
valu
highestrank
hit
select
vitro
test
use
similar
vote
system
describ
dock
solut
cast
vote
one
predict
valu
within
top
captur
hit
otherwis
cast
vote
zero
escherichia
coli
cell
presenc
carbenicillin
describ
previous
cell
harvest
centrifug
minut
pellet
store
use
merscov
pro
purif
perform
use
consecut
step
hydrophobicinteract
chromatographi
deae
anionexchang
chromatographi
mono
cationexchang
chromatographi
sizeexclus
chromatographi
describ
previous
pro
produc
purifi
use
modifi
protocol
agnihothram
et
al
final
protein
yield
calcul
base
measur
total
activ
unit
productmin
specif
activ
unitsmg
milligram
protein
obtain
biorad
protein
assay
chromatograph
step
inhibit
assay
conduct
describ
previous
acquir
hit
screen
inhibit
pro
mer
pro
concentr
duplic
assay
contain
follow
assay
buffer
hepe
mgml
bsa
dtt
compound
potent
compound
train
set
tabl
enzym
use
follow
equat
max
percent
maximum
inhibit
pro
error
ic
valu
determin
error
fit
paramet
control
perform
enzym
substrat
waswer
omit
fluoresc
attenu
control
carri
ad
inhibitor
cleav
substrat
reaction
mixtur
ident
use
inhibit
assay
figur
b
show
correspond
scatter
plot
experiment
versu
estim
bioactiv
train
test
inhibitor
n
number
train
compound
use
gener
pharmacophor
see
tabl
figur
show
pharmacophor
fit
potent
train
compound
ic
appear
aromaticbond
descriptor
combin
posit
slope
qsar
equat
indic
pro
inhibitori
activ
directli
proport
number
aromat
ring
inhibitor
structur
expect
bind
pocket
rich
aromat
amino
acid
appar
ligand
aromat
ring
stack
aromat
residu
bind
pocket
like
lead
high
bind
affin
howev
emerg
sever
dipol
tabl
furthermor
mcc
tabl
merg
pharmacophor
share
common
featur
report
improv
perform
pharmacophor
captur
activ
molecul
addit
hypo
modifi
ad
exclus
sphere
section
tabl
enhanc
roc
profil
tabl
exclus
volum
resembl
inaccess
region
within
bind
site
figur
show
steric
refin
version
figur
final
hydrogen
bond
interact
anchor
ligand
tertiari
amid
carbonyl
peptid
nh
correspond
fit
carbonyl
hba
featur
hypo
figur
find
show
hypo
repres
valid
bind
mode
exhibit
ligand
within
bind
pocket
pro
interact
highlight
pharmacophor
featur
within
model
like
critic
ligandbind
affin
structurebas
approach
dbcica
model
structurebas
pharmacophor
model
pro
obtain
use
dbcica
approach
subset
inhibitor
tabl
dock
pro
bind
pocket
use
libdock
cdocker
section
highestrank
conformerspos
base
score
function
align
togeth
construct
correspond
dbcica
model
genet
algorithm
use
search
best
combin
ligandreceptor
intermolecular
contact
capabl
explain
bioactiv
variat
across
train
compound
tabl
show
contact
distanc
threshold
number
posit
neg
contact
statist
criteria
best
dbcica
model
tabl
show
critic
bind
site
contact
atom
propos
optim
dbcica
model
highestrank
dbcica
model
exhibit
excel
statist
criteria
anticip
act
good
templat
build
correspond
pharmacophor
model
tabl
final
contact
point
neg
correl
bioactiv
assum
repres
area
steric
clash
bound
ligand
therefor
contact
use
defin
exclus
volum
within
vicin
bind
pocket
shown
figur
strategi
use
translat
optim
dbcica
model
tabl
correspond
pharmacophor
model
figur
x
z
coordin
result
pharmacophor
shown
tabl
subsequ
valid
use
roc
analysi
tabl
illustr
excel
classif
power
pharmacophor
distinguish
activ
decoy
matthew
correl
coeffici
valu
indic
structurebas
dbcica
model
superior
classif
abil
qsarguid
pharmacophor
qsarguid
steric
refin
merg
pharmacophor
hypo
dbcicabas
pharmacophor
hypo
hypo
use
search
queri
screen
nci
virtual
databas
small
molecul
inhibitor
pro
captur
hit
filter
lipinski
criteria
smart
filter
describ
hand
filter
dbcicaderiv
hit
dock
pro
protein
use
dock
condit
tabl
sever
control
perform
either
substrat
enzym
omit
assay
data
shown
none
hit
show
evid
fluoresc
interfer
might
possibl
compound
act
activ
enzym
howev
evid
still
need
support
hypothesi
previous
observ
design
revers
peptidomimet
inhibitor
act
activ
low
compound
concentr
result
induc
dimer
therefor
hit
discuss
current
public
figur
howev
compound
fail
show
signific
inhibitori
activ
pro
puriti
confirm
use
nuclear
magnet
reson
mass
spectroscopi
figur
anoth
compound
found
exhibit
bit
lower
activ
merscov
enzym
inhibit
puriti
confirm
use
nuclear
magnet
reson
mass
spectroscopi
figur
compound
nci
code
share
common
phenylsulfonamid
fragment
amen
chemic
modif
compound
captur
hypo
hypo
pharmacophor
tabl
figur
show
hit
map
dbcica
pharmacophor
model
indic
influenc
inner
filter
effect
figur
inner
filter
effect
one
major
challeng
usual
encount
fretbas
enzym
assay
low
hit
rate
observ
studi
justifi
limit
avail
mani
toprank
hit
nci
open
clearli
qualiti
train
set
pivot
factor
determin
predict
valid
obtain
pharmacophor
also
worth
note
activ
sitedirect
design
nonpeptidomimet
small
molecul
inhibitor
proteas
often
challeng
uniqu
chemistri
peptidebond
cleavag
transit
state
proteas
cleav
substrat
induc
fit
mechan
recent
special
attent
paid
bat
coronavirus
two
deadli
emerg
coronavirus
caus
unexpect
human
diseas
outbreak
sarscov
merscov
suggest
origin
bat
merscov
consid
threat
global
public
health
humantohuman
transmiss
far
limit
seriou
concern
pandem
potenti
rais
therefor
urgent
need
develop
effect
safe
antimerscov
treatment
studi
explor
pharmacophor
space
recent
identifi
peptidomem
pro
inhibitor
success
dbcica
model
translat
bind
model
pharmacophor
use
silico
screen
tool
virtual
databas
appli
robust
comput
method
model
pro
inhibitor
tool
identifi
inhibitor
merscov
pro
model
assist
identif
hit
compound
moder
appar
activ
merscov
pro
identifi
inhibitor
share
novel
nonpeptidomimet
scaffold
amen
medicin
chemistri
optim
effort
despit
fair
inhibitori
activ
scaffold
repres
potenti
start
point
discoveri
novel
merscov
antivir
sever
success
exampl
histori
drug
discoveri
start
hit
show
lowtomoder
enzym
inhibit
exampl
millimolar
inhibitor
start
point
develop
zanamivir
first
influenza
neuraminidas
inhibitor
introduc
market
importantli
establish
ligandbas
structurebas
pharmacophor
model
aid
tool
advanc
understand
small
molecul
recognit
coronaviru
pro
enzym
pharmacophor
obtain
model
